After stopping Farxiga trial early, AstraZeneca declares success in CKD treatment

Back in March, AstraZeneca announced plans to halt a Phase III trial for its Farxiga drug ahead of schedule after seeing “overwhelming efficacy” in patients with chronic kidney disease. Now, the British drugmaker is claiming a win after the drug met all primary and secondary endpoints.